Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Incannex Healthcare Limited is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are highly distributed, with each one residing in a different art unit, totaling 3 distinct art units. Furthermore, 3 distinct examiners are involved, meaning each pending action is being reviewed by a different individual. This distribution suggests a broad research and development strategy that touches multiple specialized areas of biotechnology.
TRUONG, QUANGLONG N is the busiest examiner, currently handling 1 pending office action. This distribution across 3 pending office actions, 3 distinct examiners, and 3 distinct art units indicates a diverse prosecution strategy. The company is engaging with multiple facets of the biotechnology sector simultaneously, requiring a broad approach to address the specific requirements of three different technical review groups. Practitioners should be prepared for varied feedback, as the 3 distinct examiners may have different interpretations of the 3 distinct art units' guidelines. The 3 pending office actions represent a decentralized portfolio where each application's success is independent of the others.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698191 | OIL-IN-WATER EMULSION FOR INHALATION ADMINISTRATION COMPRISING CANNABIDIOL(CBD) | TRUONG, QUANGLONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698191 | OIL-IN-WATER EMULSION FOR INHALATION ADMINISTRATION COMPRISING CANNABIDIOL(CBD) | TRUONG, QUANGLONG N | — |
| 18576218 | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule | BAEK, BONG-SOOK | — |
| 17907322 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING AN INFLAMMATORY CONDITION | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1611 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698191 | OIL-IN-WATER EMULSION FOR INHALATION ADMINISTRATION COMPRISING CANNABIDIOL(CBD) | TRUONG, QUANGLONG N | 1626 | §102§103§112 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18576218 | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule | BAEK, BONG-SOOK | 1611 | §103 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 17907322 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING AN INFLAMMATORY CONDITION | HUI, SAN MING R | 1627 | §103Other | Final Rejection | — | Pending | Sep 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIncannex Healthcare Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Quanglong N Truong has the most, with 1 of Incannex Healthcare Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
